CoChat

New vaccine coalition targets epidemics

Open access
Mullard, Asher · 2016 · Nature Reviews Drug Discovery
Cited by 64

The DOI matches its Crossref record.

Abstract

drugs with new mechanisms of action. Novel drugs accounted for 27% of the phase III cardiovascular candidates in 1990, and 57% of the candidates in 2012. “The observed contraction in cardiovascular research output may be driven by fewer follow-on drugs,” the authors note. An analysis of progression rates showed that cardiovascular drugs are just as likely to successfully complete clinical trials as other drugs, even in phase III. “Given the increasing burden of cardiovascular disease globally, the declining pipeline of new therapies is concerning. Policymakers should focus their efforts on supporting research aimed at improving gaps in the understanding of the pathophysiological bases for cardiovascular disorders, as well as facilitating translational efforts to develop new cardiovascular therapeutics,” the authors conclude. The decline in cardiovascular drug development over the past two decades Cardiovascular pipeline decline quantified

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd.2016.209

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 64

Metadata

Authors
Mullard, A.
Venue
Nature Reviews Drug Discovery
Published
2016-09-29
Volume
15
Issue
10
Pages
669-669
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2524380905
Cited by
64
References
0
FWCI
12.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New vaccine coalition targets epidemics. https://app.cochat.ai/papers/10.1038/nrd.2016.209
The paper
Mullard, A. (2016). New vaccine coalition targets epidemics. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd.2016.209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.